This study aims to develop composite materials to address immune decline and sarcopenia in the aging population. As aging progresses, reduced immunity and sarcopenia severely affect health and quality of life, requiring preventive and therapeutic solutions. In this research, effective samples related to coronavirus infection, inflammation, and sarcopenia will be selected to create composite materials and evaluate their effects. The study has three main objectives: First, the cytotoxicity of Cii and composite materials will be assessed using Raw264.7 macrophages, and protein metabolism changes induced by LPS-induced inflammation will be analyzed. Second, the cytotoxicity of the composite materials will be tested using C2C12 muscle cells, and protein metabolism changes in sarcopenia induced by dexamethasone will be observed. Third, the cytotoxicity of MPG-1 and composite materials will be evaluated using RD rhabdomyosarcoma cells, and their anti-coronavirus efficacy will be assessed by infecting cells with HCoV-OC43. Cells will be cultured in DMEM medium, and cell viability will be measured using the MTT assay. Inflammatory responses and protein expression changes will be analyzed using NO assays, MTT assays, and Western blot techniques. This study aims to explore the potential of composite materials to improve immunity and muscle health, offering practical solutions for the elderly's health.